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Abstract:	19 
Problem:	Susceptibility	to	Chlamydia	trachomatis	infection	is	increased	by	oral	20 
contraceptives	and	modulated	by	sex	hormones.	We	therefore	sought	to	determine	the	21 
effects	of	female	sex	hormones	on	the	innate	immune	response	to	C.	trachomatis	infection.	22 
	23 
Method	of	study:		ECC‐1	endometrial	cells,	pre‐treated	with	estradiol	or	progesterone,	24 
were	infected	with	C.	trachomatis	and	the	host	transcriptome	analysed	by	Illumina	Sentrix	25 
HumanRef‐8	microarray.	Primary	endocervical	epithelial	cells,	prepared	at	either	the	26 
proliferative	or	secretory	phase	of	the	menstrual	cycle,	were	infected	with	C.	trachomatis	27 
and	cytokine	gene	expression	determined	by	quantitative	RT‐PCR	analysis.		28 
	29 
Results:	C.	trachomatis	yield	from	progesterone‐primed	ECC‐1	cells	was	significantly	30 
reduced	compared	to	estradiol‐treated	cells.	Genes	up‐regulated	in	progesterone	treated	31 
and	Chlamydia‐infected	cells	only	included	multiple	CC	and	CXC	chemokines,	IL‐17C,	IL‐29,	32 
IL‐32,	TNF,	DEFB4B,	LCN2,	S100A7‐9,	ITGAM,	NOD2,	JAK1,	IL‐6ST,	type	I	and	II	interferon	33 
receptors,	numerous	interferon‐stimulated	genes	and	STAT6.	CXCL10,	CXCL11,	CX3CL1	and	34 
IL‐17C	were	also	up‐regulated	in	infected	secretory	stage	primary	cells	and	there	was	a	35 
trend	towards	higher	levels	of	immune	mediators	in	infected	secretory	phase	compared	to	36 
proliferative	phase	cells.	37 
		38 
Conclusions:		Progesterone	treatment	primes	multiple	innate	immune	pathways	in	39 
hormone‐responsive	epithelial	cells	that	could	potentially	increase	resistance	to	40 
chlamydial	infection.	41 
	42 
	43 
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Introduction:	46 
Chlamydia	trachomatis	is	an	obligate,	intracellular	bacterial	pathogen	that	causes	47 
salpingitis,	pelvic	inflammatory	disease,	ectopic	pregnancies	and	infertility	as	well	as	48 
blinding	trachoma.	The	initial	target	cells	of	C.	trachomatis	genital	serovars	are	the	49 
epithelial	cells	of	the	endocervix	in	women	and	the	penile	urethra	in	men.	Both	in	vivo	and	50 
in	vitro	studies	have	shown	that	the	female	sex	hormones	estradiol	and	progesterone	affect	51 
susceptibility	to	infection.	For	example,	oral	contraceptive	use	increases	the	risk	of	52 
contracting	chlamydial	infections	1.	Estradiol	treatment	of	HeLa	cells	enhances	both	53 
chlamydial	adherence	to	cells	and	the	development	of	chlamydial	inclusions	whist	54 
progesterone,	in	combination	with	estradiol	reduced	chlamydial	adherence	2.	Using	55 
porcine	primary	genital	tract	epithelial	cells,	Wyrick	et	al.	3	showed	that	cells	isolated	at	the	56 
estrogen‐dominant	phase	of	the	cycle	were	more	susceptible	to	infection	with	C.	suis	than	57 
cells	isolated	from	the	progesterone	dominant	stage	of	cycle.	In	the	mouse	model	of	C.	58 
muridarum	infection,	pre‐treatment	with	progesterone	is	required	to	achieve	infection	of	59 
100%	of	animals.	Conversely,	guinea	pigs	are	more	susceptible	to	infection	after	priming	60 
with	estradiol.		Within	the	female	reproductive	tract	(FRT)	the	need	to	protect	against	61 
sexually	transmitted	pathogens	must	be	balanced	against	the	need	to	sustain	the	62 
development	of	an	allogeneic	fetus.	Because	of	this	unique	requirement	many	aspects	of	63 
both	innate	and	adaptive	immunity	in	the	FRT	are	regulated	by	changes	in	female	sex	64 
hormones.	These	include	the	expression	of	chemokine	receptors	(CXCR4	and	CCR5),	65 
production	of	inflammatory	cytokines	and	chemokines	(IL‐6	and	CXCL8/IL‐8)	and	66 
antimicrobial	peptides	such	as	SLPI,	HBD2	and	lactoferrin	4.	Neutrophil	and	monocyte	67 
numbers	also	fluctuate	throughout	the	reproductive	cycle	5	as	do	the	IgG	and	IgA	levels	in	68 
reproductive	tract	secretions	4,	the	numbers	of	CD8	cells,	B	lymphocytes	and	monocytes	in	69 
endometrial	lymphoid	aggregates	6,	endometrial	NK	cell	numbers	7	and	CTL	activity	of	CD8	70 
cells	isolated	from	hysterectomy	tissues	8.	Less	information	is	available	however	on	how		71 
female	sex	hormones	affect	the	innate	immune	response	of	FRT	epithelial	cells,	the	initial	72 
cell	type	targeted	by	Chlamydia.	Furthermore,	changes	in	these	sex	hormones	control	all	73 
aspects	of	tissue	remodelling	in	preparation	for	possible	fertilization	and	implantation.	74 
Because	the	effects	of	the	female	reproductive	hormones	are	profound,	often	modulating	75 
global	gene	expression,	we	have	used	a	gene	array	approach	to	investigate	how	sex	76 
hormone	treatment	of	hormone‐responsive	ECC‐1	cells	affects	the	early	(12	hours)	and	late	77 
(24	hours)	innate	immune	response	to	chlamydial	infection.	Primary	endocervical	cells	78 
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were	also	isolated	from	hysterectomy	tissues	collected	at	either	the	secretory	or	79 
proliferative	stage	of	the	menstrual	cycle	and	infected	with	C.	trachomatis.	Based	on	80 
changes	in	gene	expression	patterns	seen	in	hormone	pre‐treated	and	infected	ECC‐1	cells	81 
the	expression	of	selected	innate	immune	response	genes	was	assayed	in	infected	primary	82 
epithelial	cells	using	quantitative	RT‐PCR.		Data	from	both	the	cell	line	and	primary	cell	83 
studies	show	that	progesterone	activates	multiple	innate	immune	pathways	that	could	84 
reduce	susceptibility	to	chlamydial	infection.		85 
	 	86 
  Page 5 of 31
Materials	and	Methods:	87 
This	study	was	approved	by	the	Human	Research	Ethics	Committee	of	the	University	of	88 
Newcastle	and	Hunter‐New	England	Health.	Written	informed	consent	was	obtained	from	89 
all	study	participants	90 
Cell	culture	and	chlamydial	infection	91 
The	ECC‐1	cell	line	derived	from	the	human	uterine	endometrial	functional	zone	9	was	a	92 
gift	from	Dr	John	Fahey,	Department	of	Physiology,	Dartmouth	College.		ECC‐1	cells	were	93 
cultured	in	24‐well	plates	(Nunc)	on	10mm	diameter	coverslips	to	80%	confluence,	before	94 
the	addition	of	of	17‐estradiol	(200	pg/mL),	progesterone	(20	ng/mL)	(both	Sigma‐95 
Aldrich)	or	a	combination	of	both	hormones,	in	phenol	red	and	antibiotic‐free	DMEM/F12	96 
medium	supplemented	with	10%	charcoal/dextran‐treated	FBS	(Invitrogen),	for	24	hrs.	97 
The	confluent	cells	(~5x105	cells)	were	infected	with	5x105	I.F.U.	of	C.	trachomatis	serovar	98 
D	(multiplicity	of	infection	[MOI]	=1).	Plates	were	centrifuged	at	400	xg	for	45	min	at	RT,	to	99 
facilitate	infection.	After	4	hours	cells	were	washed	3X	to	remove	surface‐adherent	100 
Chlamydia	and	then	incubated	for	12	or	24	hrs	at	370C/5%	CO2.		101 
Isolation	of	primary	human	endocervical	epithelial	cells.	102 
Endocervical	tissues	were	obtained	from	women	undergoing	hysterectomy,	with	an	age	103 
range	of	31‐55	years	(average	age	42.2	years).	The	stage	of	the	menstrual	cycle	was	104 
determined	by	a	pathologist.	Tissues	were	collected	from	women	undergoing	105 
hysterectomy	for	fibroids,	dysmenorrhea	and	prolapse	but	not	from	women	with	known	106 
cancer	or	a	history	of	abnormal	cervical	cells.		Epithelial	cells	were	isolated	as	described	by	107 
Wira	et	al.	10.	Briefly,	the	epithelium	was	separated	from	underlying	stromal	tissues	by	108 
scraping	the	luminal	surface	with	a	scalpel.		Epithelial	tissues	were	then	minced	under	109 
sterile	conditions	into	1‐2	mm	fragments	and	digested	for	2	hours	with	an	enzyme	solution	110 
containing	pancreatin	(3.4	mg/ml,	Invitrogen),	hyaluronidase	(0.1	mg/ml,	Sigma‐Aldrich)	111 
and	collagenase	(1.6	mg/ml,	Sigma‐Aldrich)	in	HBSS	supplemented	with	2	mg/ml	D‐112 
glucose.	Cells	were	then	dispersed	through	a	250	m	mesh	screen,	washed	and	suspended	113 
in	phenol	red‐free	DMEM/F12	medium	containing	10%	charcoal/dextran‐stripped	FCS	114 
(Invitrogen)	20	mM	HEPES,	50	U/ml	(Invitrogen),	Primocin	(InvivoGen)	and	2	mM	L‐115 
glutamine	(Invitrogen,	Complete	medium).	Epithelial	sheets	were	separated	from	stromal	116 
cells	by	filtration	through	a	40	m	mesh,	washed	by	centrifugation	and	resuspended	in	117 
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complete	medium.	Epithelial	sheets	were	aliquoted	to	24	well	plates	pre‐coated	with	118 
Human	Extracellular	Matrix	(BD	Biosciences)	and	cultured	in	complete	medium	until	119 
confluent	(usually	5‐7	days).	Cells	were	then	rinsed	twice	with	complete	medium	without	120 
Primocin	and	infected	with	C.	trachomatis	serovar	D	or	L2	(5	x	106	IFU)	by	centrifugation	121 
(Beckman	J‐6M/E	centrifuge,	1000	rpm	for	45	min	at	22oC)	and	then	cultured	for	a	further	122 
24	hours.	RNA	was	then	prepared	by	Trizol	extraction	(Sigma‐Aldrich).	123 
	124 
Sample	preparation	for	Microarray	analysis	125 
At	12	and	24	hours	post‐infection	DNA	and	mRNA	were	isolated	from	triplicate	wells	of	126 
hormone‐treated	and	control	ECC‐1	cells	using	the	Trizol	extraction	method	according	to	127 
the	manufacturer’s	instructions.	The	resultant	RNA	was	resuspended	in	10	L	ddH20	and	128 
mRNA	purified	using	the	Pure‐link	RNA	extraction	kit	(Invitrogen),	according	to	the	129 
manufacturer’s	instructions.	Separately,	the	DNA	component	from	the	Trizol	separation	130 
was	purified	following	the	manufacturer’s	instruction.	The	final	eluate	for	all	reactions	was	131 
collected	in	a	40	L	volume	and	quantified	using	a	NanoDrop	spectrophotometer	(Thermo	132 
Scientific)	before	being	used	for	microarray	or	RT‐PCR	analysis.	133 
	134 
Illumina	Microarray	hybridisation	and	analysis	135 
Total	RNA	was	extracted	using	the	RNeasy	Mini	Kit	(Qiagen)	and	quantified	using	the	136 
Quant‐iT	RiboGreen	RNA	Quantitation	Assay	Kit	(Invitrogen),	with	the	fluorescence	137 
measured	on	the	FLUOstar	Optima	(BMG	LABTECH)	at	485	nm	for	excitation	and	520	nm	138 
for	emission.	A	total	of	500	ng	RNA	was	reverse	transcribed	into	cRNA	and	labelled	with	139 
biotin‐uridine	triphosphate	using	the	Illumina	TotalPrep	RNA	Amplification	Kit	(Applied	140 
Biosystems).	A	total	of	850	ng	cRNA	was	hybridised	to	Illumina	Sentrix	HumanRef‐8	v1.1	141 
Expression	BeadChips	(Illumina)	using	standard	protocols.	Each	BeadChip	measured	the	142 
expression	of	24,354	genes	and	was	scanned	using	the	Illumina	Bead	Station	and	captured	143 
using	BeadScan	3.5.11	(Illumina).	For	whole‐genome	gene	analysis,	data	were	initially	144 
cubic	spline	normalised	using	BeadStudio	2.0	software	(Illumina),	and	each	individual	gene	145 
was	normalised	to	the	median	using	GeneSpring	GX	11.0,	resulting	in	two‐way	146 
normalisation.	147 
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Genes	were	judged	to	be	differentially	regulated	only	when:	(1)	the	gene	was	present	in	all	148 
(triplicate)	samples	studied,	(2)	the	difference	in	expression	was	>1.5‐fold,	and	(3)	the	149 
extent	of	difference	in	expression	was	significant	(p<0.05	in	Wilcoxon–Mann–Whitney	test).	150 
The	microarray	data	can	be	accessed	via	the	Gene	Expression	Omnibus	(GEO)	database	151 
(GSE31149)	and	is	compliant	with	MIAME	guidelines.	152 
	153 
First‐strand	synthesis	of	C.trachomatis	D‐infected	ECC‐1	mRNA	154 
First‐strand	cDNA	synthesis	from	the	24	hours	timepoint	was	performed	with	the	155 
Superscript	III	first‐strand	synthesis	kit	(Invitrogen)	following	the	manufacturer’s	156 
instructions.	0.5	mL	of	each	RNA	extract	was	used	with	oligo‐dT	to	generate	host‐specific	157 
cDNA	for	comparative	analysis.	158 
	159 
Quantitative	real‐time	reverse	transcriptase	PCR	analysis	160 
	Quantitative	reverse	transcriptase	polymerase	chain	reaction	(qRT‐PCR)	was	used	to	161 
confirm	the	accuracy	and	expression	trends	of	the	microarray	data	from	infected	ECC‐1	162 
cells	and	to	determine	cytokine	transcript	levels	in	C.trachomatis‐infected	primary	163 
epithelial	cells	using	intron‐spanning,	gene‐specific	primers.	The	primers	used	in	the	164 
validation	of	the	microarray	data	were	designed	using	the	software	Oligo	(Molecular	165 
Biology	Insights)	and	confirmed	online	using	NCBI’s	Primer‐BLAST	tool	166 
(http://www.ncbi.nlm.nih.gov/tools/primer‐blast/).	Primer	sequences	are	provided	in	167 
Error!	Reference	source	not	found.Table	1.	Individual	PCR	reactions,	containing	5	L	of	168 
the	Platinum	SYBR	super‐mix	(Invitrogen),	1	M	of	each	forward	and	reverse	primers	169 
(Sigma	Aldrich)	and	1	L	of	template	in	a	final	reaction	volume	of	10	L	were	used.	170 
The	transcript	levels	from	infected	primary	endocervical	cells	were	measured	using	the	171 
Taqman	Gene	Expression	Assay	(Applied	Biosystems)	following	the	manufacturer's	172 
protocols.	Details	of	the	Taqman	gene	expression	assay	used	are	summarised	in	Error!	173 
Reference	source	not	found.Table	1.	QRT‐PCR	data	was	collected	on	the	Rotorgene	Q	174 
(Qiagen)	version	1.7.94.	A	standard	curve	for	each	gene	was	constructed	using	genomic	175 
DNA	extracted	from	the	ECC‐1	cell	line,	amplified	via	conventional	PCR	and	purified	via	176 
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Pure‐link	PCR	columns	(Invitrogen).	A	100‐fold	dilution	series	was	constructed	with	177 
concentrations	ranging	from	108	to	102	copies/mL.		178 
A	standardised	protocol	of	an	initial	incubation	at	950C	for	10	min,	followed	by	a	179 
touchdown	protocol	of	940C	for	45	sec,	700C‐600C	for	15	sec	decreasing	by	10C	each	cycle,	180 
and	720C	for	20	sec	for	a	total	of	10	cycles,	followed	with	30	cycles	of	940C	for	45	sec,	600C	181 
for	15	sec	and	720C	for	20	sec	was	used.	Real‐time	data	acquisition	for	fluorescence	was	182 
taken	upon	completion	of	the	extension	step.	Melt	curve	analysis	was	performed	between	183 
750C	and	950C	at	a	10C	intervals,	holding	for	5	seconds	at	each	interval	to	confirm	the	184 
extension	of	the	correct	homogenous	product.	All	samples	(cDNA	and	gDNA)	were	185 
amplified	in	triplicates,	and	then	compared	to	freshly	diluted	standard	curves	(amplified	in	186 
duplicates).	Interrogation	of	each	gene	product	was	performed	within	the	same	run	to	187 
eliminate	inter‐run	variability.	Quantitation	of	chlamydial	genomic	DNA	and	cDNA	of	the	188 
transcripts	was	performed	using	Chlamydia	specific	primers	for	the	chlamydial	16SrRNA	189 
ORF.	Amplification	involved	an	initial	denaturation	step	at	940C	for	10	min,	then	40	cycles	190 
at	940C	for	30	sec,	500C	for	15	sec	then	extension	at	720C	for	30	sec	followed	by	data	191 
acquisition	at	the	end	of	the	extension.		192 
Ingenuity	Pathway	Analysis	of	up‐regulated	interferon	regulated	genes	193 
Ingenuity	Pathway	Analysis	software	(version	8.5)	was	used	to	examine	the	degree	of	194 
global	up‐regulation	mediated	by	each	of	the	hormone	+	infection	conditions.	Linkages	and	195 
associations	were	made	with	genes	that	are	up‐regulated	under	progesterone	only	196 
treatment,	and	dual	hormonal	effect.	A	system	default	parameter	was	used	in	all	analysis,	197 
to	link	conical	pathways	with	up‐regulated	genes,	and	neighbourhood	linkage,	unless	198 
otherwise	stated.	The	status	of	each	hormone‐mediated	up‐regulated	gene	from	the	199 
different	treatments	was	tallied	against	the	Interferome	database	(http://interferome.org/)	200 
to	establish	whether	its	regulation	is	affected	by	the	presence	of	interferon‐gamma	(IFN)	201 
in	previously	published	literature.		202 
	 	203 
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Results:	204 
Effect	of	sex	hormone	supplementation	on	C.	trachomatis	infection	of	ECC‐1	cells.	205 
To	determine	if	sex	hormones	affected	chlamydial	infection	of	ECC‐1	cells	we	measured		206 
total	chlamydial	genomic	DNA	at	24	hrs	post‐infection	(p.i.)	by	qPCR,	targeting	the	207 
chlamydial	16S	ribosomal	RNA	(16S	rRNA).	The	number	of	chlamydial	genomes	was	208 
calculated	from	the	geometric	mean	of	16S	rRNA	triplicates	of	each	hormone	treatment.		209 
After	accounting	for	the	fact	that	C.	trachomatis	has	two	copies	of	the	16S	rRNA	gene,	the	210 
number	of	Chlamydia	in	progesterone‐treated	ECC‐1	cells	was	found	to	be	significantly	211 
lower	than	in	the	other	hormone	treatments,	as	well	as	the	no	hormone	condition.	Analysis	212 
using	one‐way	ANOVA	indicates	a	statistically	significant	reduction	in	Chlamydia	between	213 
progesterone‐only	exposure	and	dual	hormone	exposure	(p<0.008),	and	between	the	214 
progesterone	and	no	hormone	treatment	(p<0.013,	Figure	1).	No	significant	difference	215 
between	estradiol	treatment	and	progesterone	treatment	(p<0.081)	was	found,,	probably		216 
due	to	the	high	variance	within	the	estradiol‐treated	triplicates.	In	progesterone‐treated	217 
ECC‐1	cells,	C.trachomatis	copy	number	was	almost	10‐fold	lower	than	cells	treated	with	218 
both	hormones	together	(Figure	1)	indicating	that	the	suppressive	effect	of	progesterone	219 
on	chlamydial	infection	is	negated	by	estradiol.		220 
	221 
Global	gene	expression	profiling	under	different	hormone	treatments.	222 
We	then	compiled	global	gene	expression	profiles	for	ECC‐1	cells	treated	with	hormones	223 
alone,	or	pre‐treated	with	hormones	prior	to	chlamydial	infection,	at	both	12	and	24	hrs,	224 
after	normalising	against	similarly	treated	no	hormone	and	no	infection	controls.	This	is	225 
summarised	in	Figure	2.		From	a	total	of	22184	genes	on	the	microarray,	the	number	of	226 
differentially	expressed	genes	that	were	significantly	changes	at	12	hrs	(Figure	2A)	was	227 
2552	(315	up,	2237	down;	11.5%	of	the	genome)	for	estradiol,	2716	(400	up,	2316	down;	228 
12.24%)	for	progesterone,	and	2638	(342	up,	2296	down;	11.89%)	for	both	hormones	229 
together.	At	24	hrs	(Figure	2B),	the	number	of	genes	that	were	differentially	expressed	230 
dropped	to	1461	(980	up,	481	down;	6.59%)	for	estradiol,	585	(385	up,	200	down;	2.64%)	231 
for	progesterone,	and	2429	(1500	up,	929	down;	10.95%)	for	both	hormones.	When	232 
infected	with	Chlamydia,	the	number	of	significant	differentially	expressed	genes	at	12	hrs.	233 
numbered	1871	(1274	up,	597	down;	8.43%)	for	estradiol,	1647	(874	up,		773	down;	234 
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7.42%)	for	progesterone,	and	2024	(1219	up,	805	down;	9.12%)	for	both	hormones.	At	24	235 
hrs	p.i.,	the	number	of	genes	significantly	altered	changed	to	1658	(1090	up,	568	down;	236 
7.47%),	1842	(1489	up,	353	down;	8.30%),	and	1381	(831	up,	550	down;	6.23%)	for	237 
estradiol,	progesterone,	or	both	hormones	respectively.	238 
Induction	of	cytokines,	chemokines,	and	immune‐related	gene	expression	in	the	human	239 
ECC‐1	cells	by	progesterone	alone.	240 
To	establish	the	potential	mechanism(s)	that	limit	chlamydial	growth	in	the	presence	of	241 
progesterone,	we	focused	on	the	immune	response	genes	encoding	innate	immunity	242 
components,	signal	transducers	and	transcriptional	modulators.	Genes	significantly	up‐243 
regulated	by	progesterone	but	not	estradiol	or	a	combination	of	both	hormones	were	244 
identified	and	categorised	either	as	a	positive	or	negative	interferon‐gamma‐response	245 
genes	(IRG)	using	the	online	Interferome	database	(http://interferome.org)	because	both	246 
type	I	and	type	II	interferon	pathways	have	been	implicated	in	both	clearance	of	Chlamydia	247 
and	chlamydial	inflammation.	Table	2	summarises	the	chemokines,	cytokines	and	immune‐248 
related	genes	that	were	up‐regulated	at	the	12	and	24	hours	in	progesterone	pre‐treated	249 
cells	plus	or	minus	infection	with	C.	trachomatis	D	250 
.	251 
Progesterone‐specific	up‐regulated	genes	in	non‐infected	cells	at	12	and	24	hrs	included	252 
two	chemokines	(CXCL13	[2.6‐fold]	at	12	hrs	and	CXCL7/PPBP	[3.3‐fold]	at	24	hrs).	Three	253 
cytokine	genes	(IL‐2	[1.8‐fold],	IL‐19	[1.5‐fold]	and	IL‐24	[3.2‐fold]	were	all	increased	at	12	254 
hrs.	Four	immune‐related	genes	(ITFG1	[6‐fold]	at	12	hrs	and	DEFB108B	[2.7‐fold],	IL‐255 
20RB	[3‐fold]	and	SOCS4	[1.5‐fold]	at	24	hrs)	were	also	increased	in	progesterone‐treated	256 
cells.	All	genes	were	classified	as	IRG‐,	with	the	exception	of	CXCL7/PPBP,	according	to	the	257 
interferome	database.		258 
	259 
When	progesterone	pre‐treated	ECC‐1	cells	were	infected	with	C.	trachomatis,	the	number	260 
of	up‐regulated	transcripts	was	more	pronounced.	At	12	hrs.,	there	was	an	elevated	261 
production	of		defensins	(DEFB104A,	DEFB129,	DEFB137)	as	well	as	the	defensin,	262 
DEFA4	and	transcripts	for	the	receptors	for	IL‐6	and	CXCL8/IL‐8	(2‐	and	3‐fold,	263 
respectively).	Consistent	with	the	observed	recruitment	of	leukocytes	into	Chlamydia‐264 
infected	tissues,	transcripts	encoding	multiple	chemokines,	both	CC	and	CXC,	were	265 
significantly	increased	at	12	and	particularly	24	hours.	At	12	hours	p.i.,	the	expression	of	266 
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CCL4	(recruitment	of	monocytes,	NK	cells,	and	dendritic	cells)	and	CXCL12	(recruitment	of	267 
neutrophils,	monocytes,	T‐	and	B‐cells)	were	increased	by	2.8	and	2.6‐fold	respectively.	268 
Transcripts	encoding	matrix	metalloproteases	(MMP3,	MMP7	and	MMP25)	and	peptides	of	269 
the	S100	family	(S100A2	at	12	and	24	hours	and	S100A3/7/8/9	at	24	hours)	were	also	270 
detected.	Included	among	the	many	functions	of	S100	family	proteins	are	leukocyte	271 
chemoattraction,	anti‐microbial	activity	and	pro‐inflammatory	functions	11.	272 
	273 
After	prolonged	exposure	to	the	pathogen,	there	was	increased	transcription	of	multiple	274 
IRG+	and	IRG‐	genes.	Notable	among	these	were	CXCL8/IL‐8	[5.8‐fold],	CCL20	[8‐fold],	275 
CXCL2	[6.3‐fold],	CXCL11	[6.3‐fold],	and	CX3CL1	[7.6‐fold].	Three	of	these	chemokines	276 
(CCL20,	CXCL2	and	CXCL11)	possess	potent	antimicrobial	activity.	Interestingly,	transcript	277 
products	encoding	TNF	[4.42‐fold],	IL‐1	[4.8‐fold],	IL‐6	[4.1‐fold],	IL‐17C	[8.1‐fold],	IL‐21	278 
[5.3‐fold]	and	IL‐23A/p19	[3‐fold]	were	up‐regulated	in	concert.	The	gene	for	IL‐29,	a	type	279 
3	interferon	was	up‐regulated	[2.1‐fold]	at	12	hours	and	transcripts	encoding	the	pro‐280 
inflammatory	cytokine	IL‐32	were	increased	[2.6‐fold]	at	24	hours.	281 
	282 
One	of	the	variant	IL‐6ST	(gp130)	genes,	a	component	of	the	receptor	for	the	IL‐6	family	of	283 
cytokines,	was	increased	by	11‐fold	along	with	the	gene	for	its	ligand	IL‐6.	Transcript	284 
products	associated	with	signal	transduction	and	transcriptional	modulators	were	found	to	285 
be	up‐regulated	as	well:	with	JAK1	[6.2‐fold],	STAT5A	[3.8‐fold],	NOD2	[2.81‐fold],	STAT6	286 
[2.3‐fold],	SOCS1	[4‐fold]	and	SOCS4	[1.6‐fold]	being	the	most	prominent.	Increased	287 
expression	of	some	cytokine	receptors	were	also	detected,	with	IFNAR1	[2.3‐fold],	IFNAR2	288 
[2‐fold],	IFNGR2	[3.5‐fold]	and	IL‐18R1	[2.5‐fold]	transcripts	being	up‐regulated.	Various	289 
membrane	adhesion	molecules	were	also	up‐regulated:	ICAM1	[3.9‐fold],	ITGAM	[2.5‐fold],	290 
and	ITGB8	[3.2‐fold]	all	of	which	serve	a	role	in	intercellular	attachment.	291 
	292 
	293 
Quantitative	PCR	verification	of	microarray	data.	294 
Using		qRT‐PCR,	five	up‐regulated	genes	were	randomly	chosen	(CCL20,	CX3CL1,	CXCL8/IL‐295 
8,	INFAR1	and	CXCL11)	to	verify	the	accuracy	and	reliability	of	our	microarray	data.	296 
Complementary	DNA	for	each	gene	from	respective	hormone‐treatments	were	quantified,	297 
then	normalised	against	the	copy	number	of	their	respective	genomic	counterparts.	From	298 
the	resultant	ratio	the	level	of	fold	change	was	calculated,	comparing	infected	and	non‐299 
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infected	cell	lines	exposed	to	similar	hormone	conditions.	In	all	cases	the	trend	of	up‐300 
regulation	for	the	qPCR	data	mirrors	our	microarray	data	(Figure	3).	301 
Increased	expression	of	cytokine	and	chemokine	genes	in	human	secretory	phase	302 
primary	endocervical	cells.	303 
Quantitative	RT‐PCR	was	used	to	compare	expression	levels	of	selected	304 
cytokines/chemokines	in	primary	endocervical	cells,	collected	at	either	the	secretory	or	305 
proliferative	phases	of	the	menstrual	cycle	(Figure	4).	The	genes	were	chosen	based	on	306 
those	that	were	changed	following	progesterone	treatment	and	infection	of	ECC‐1	cells.		307 
Statistically	significant	differences	in	the	levels	of	transcription	in	C.	trachomatis	D	infected	308 
primary	cells,	collected	at	the	estradiol	dominant	proliferative	phase	compared	to	the	309 
progesterone	dominant	secretory	phase,	were	seen	for	CXCL10	(p<0.0171),	CXCL11	310 
(p<0.0098)	and	IL‐17C	(p<0.048),	with	the	highest	expression	levels	seen	in	the	secretory	311 
phase	cells.	Infection	of	primary	endocervical	cells	with	a	second	C.	trachomatis,	serovar	L2	312 
also	resulted	in	higher	expression	of	transcripts	for	CXCL10	(p<0.0441)	and	CXCL11	313 
(p<0.019)	in	secretory	phase	cells	(data	not	shown).	For	all	of	the	mediators	tested	there	314 
was	a	trend	towards	higher	expression	of	transcripts	following	infection	of	cells	collected	315 
at	the	secretory	phase	of	cycle.	316 
317 
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Discussion:	318 
Chlamydia	trachomatis	is	the	most	common	bacterial	sexually	transmitted	pathogen	319 
worldwide	and	a	major	cause	of	pelvic	inflammatory	disease	(PID),	ectopic	pregnancy	and	320 
tubal	factor	infertility.	Previous	studies	have	shown	that	infection	rates	are	lower	during	321 
the	progesterone‐dominant	secretory	phase	of	the	female	menstrual	cycle.	The	influence	of	322 
female	sex	hormones	on	chlamydial	infectivity	is	also	supported	by	studies	in	animal	323 
models	and	in	in	vitro	studies	using	hormone‐responsive	cell	lines.		Understanding	the	324 
mechanism(s)	whereby	hormones	affect	susceptibility	to	infection	may	provide	important	325 
insights	into	understanding	and	controlling	infection‐induced	pathology	and	also	the	326 
development	of	an	effective	vaccine.	To	determine	if	progesterone	modulated	innate	327 
immune	responses	to	infection,	we	investigated	the	global	gene	expression	in	hormone‐328 
responsive	ECC‐1	cells,	pre‐treated	with	physiological	concentrations	of	progesterone,	329 
prior	to	infection	with	C.	trachomatis.			330 
To	confirm	the	suppressive	effect	of	progesterone	on	intracellular	infections,	we	monitored	331 
the	genomic	copies	of	Chlamydia	under	the	different	hormonal	conditions,	and	found	a	5‐332 
10‐fold	reduction	of	Chlamydia	in	ECC‐1	cells	pre‐treated	with	progesterone.	Under	the	333 
effect	of	progesterone	alone	there	was	also	a	significant	global	suppression	of	gene	334 
expression	(10.46%)	at	12	hours,	however	estradiol	pre‐treatment	also	caused	a	similar	335 
suppression	of	gene	expression	(10.08%).	While	less	than	2%	of	genes	were	up‐regulated	336 
by	progesterone	treatment	alone	at	either	12	or	24	hours,	chlamydial	infection	resulted	in	337 
an	increase	in	the	number	of	up‐regulated	genes	at	both	12	(3.94%)	and	24	(6.71%)	hours.	338 
Increased	levels	of	gene	expression,	following	infection	of	estradiol‐treated	cells	was	less	339 
evident,	only	increasing	from	4.42%	to	4.91%	of	total	genes.		340 
To	define	the	immune	components	involved	in	the	reduced	number	of	C.trachomatis	341 
recovered	from	progesterone‐treated	cells,	we	filtered	the	list	of	statistically	significant	342 
candidate	genes	that	were	up‐regulated	in	uninfected	progesterone‐treated	cells,	but	not	in	343 
estradiol‐treated	cells.	Prior	to	infection,	there	was	a	significant	up‐regulation	of	two	344 
chemokine	genes	(CXCL13	and	CXCL7)	in	progesterone‐primed	cells	compared	to	345 
estradiol‐primed	cells.	Genes	encoding	IL‐2,	IL‐19	and	IL‐24	were	also	increased,	as	were	346 
the	ITFG1,	DEFB108B	and	IL20RB	genes.	Of	these	genes	only	the	gene	encoding	CXCL7	was	347 
regulated	by	interferon	(IRG+).	Thus,	progesterone	alone	enhances	expression	of	genes	348 
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encoding	chemokines	that	recruit	and	activate	neutrophils	and	have	direct	antimicrobial	349 
activity	(CXCL7)	and	B	lymphocytes	(CXCL13).	Also	up‐regulated	was	the	‐defensin	gene	350 
DEFB108B	together	with	genes	encoding	the	IL‐10	cytokine	family	members	(IL‐19	and	IL‐351 
24)	and	a	component	of	one	of	the	receptors	used	by	this	cytokine	family	(IL‐20RB).	Little	352 
is	known	regarding	the	functions	of	IL‐19	and	IL‐24	although	both	may	have	roles	in	353 
antibacterial	responses,	tissue	remodelling,	have	tumour	suppressor	activity	and	are	354 
implicated	in	psoriasis	12.	The	gene	encoding	the	T	cell	immunomodulatory	protein	ITFG1	355 
was	increased	6‐fold	within	12	hrs	of	progesterone	priming.	These	data	suggest	that	356 
progesterone,	even	prior	to	infection,	activates	components	of	both	the	innate	(defensin	357 
production	and	neutrophil	recruitment)	and	adaptive	(B	cell	recruitment,	modulation	of	T	358 
cell	function)	immune	responses	within	ECC‐1	cells.	359 
Following	infection	the	transcriptome	in	progesterone‐primed	ECC‐1	cells	was	radically	360 
different.	At	12	hours	post	infection	genes	encoding	CCL4	and	CXCL12	were	both	up‐361 
regulated	and	at	24	hours	post‐infection	there	was	coordinate	up	regulation	of	multiple	CC	362 
and	CXC	chemokines	as	well	as	CX3CL1.	Increased	gene	expression	ranged	between	1.7	and	363 
8	fold	and	the	chemokines	were	split	equally	between	those	that	were	regulated	by	364 
interferons	(IRG+)	and	those	that	were	not	(IRG‐).	Many	of	these	chemokines	have	broad‐365 
spectrum	antimicrobial	activity	against	both	Gram	negative	and	Gram‐positive	bacteria	13.	366 
CCL5	also	has	anti‐viral	activity	against	HSV‐1		14	while	CXCL9	is	active	against	Neisseria	15,	367 
both	sexually	transmitted	pathogens.	Consistent	with	their	chemokine	designation	this		368 
spectrum	of	up‐regulated	chemokine	genes	would	result	in	the	recruitment	of	most	369 
leukocyte	subsets	to	the	site	of	infection	including	neutrophils	(CXCL8/IL‐8,	CCL20,	CXCL2),	370 
dendritic	cells	(CCL2),	monocyte/macrophages	(CCL2,	CXCL10,	CX3CL1),	NK	cells	(CXCL10)	371 
and	T	lymphocytes	including	Th1	and	T	memory	cells	(CCL2,	CXCL10,	CXCL11,	CX3CL1)	16.	372 
Some	of	these	chemokines	also	promote	adhesion	of	immune	cells	to	endothelial	and	373 
epithelial	cells	(CX3CL1	and	CXCL10)	and	have	been	implicated	in	the	de	novo	formation	of	374 
lymphoid	tissues	(CCL20)	17.	Interestingly,	the	activity	of	many	chemokines	can	be	375 
modulated	by	matrix	metalloproteinases	(MMPs)	18	and	4	MMP	genes	were	up‐regulated	376 
more	than	2.5‐fold	in	progesterone‐primed	Chlamydia‐infected	cells.	MMPs	are	also	377 
involved	in	immune	cell	recruitment	and	attachment	through	degradation	of	extracellular	378 
matrix	proteins	and	receptor	modulation	and	also	implicated	in	inflammatory	tissue	379 
damage	19.	We	also	used	qRT‐PCR	to	look	at	expression	of	selected	chemokines	in	380 
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Chlamydia‐infected	primary	human	endocervical	cells	(Figure	4).	Two	CXC	chemokines	381 
(CXCL10	and	CXCL11),	two	CC	chemokines	(CCL2	and	CCL20)	and	CX3CL1	were	all	382 
expressed	in	infected,	secretory	phase	cells	at	higher	levels	than	in	infected	proliferative	383 
phase	cells	when	estradiol	is	dominant,	supporting	our	cell	line	data	showing	that	384 
progesterone	treatment	primes	cells	to	respond	in	a	more	robust	manner	to	infection.		385 
Consistent	with	previous	studies	of	chlamydial	infection,	genes	encoding	IL‐1 ・,	IL‐6,	386 
CXCL8/IL‐8	and	TNF	were	all	up‐regulated	in	progesterone‐primed	infected	cells,	as	were	387 
components	of	the	IL‐6	(IL‐6ST/GP130	[>11‐fold])	and	CXCL8/IL‐8	(IL‐8RB/CXCR2)	388 
receptors.	Coordinate	expression	of	these	4	cytokines	is	a	common	signature	associated	389 
with	many	bacterial	infections	and	inflammatory	responses.	In	addition,	two	other	IL‐1	390 
family	genes	(IL‐1F8	and	IL‐1F9)	and	several	defensin‐encoding	genes	(both		and	)	were	391 
up‐regulated	in	progesterone‐primed	infected	cells,	together	with	several	members	of	the	392 
S100	family	of	proteins	(Calgranulins),	which	have	antimicrobial	activity	11	and	also	393 
regulate	inflammation,	cell	growth	and	differentiation	20,21.		394 
Genes	encoding	IL‐15,	a	growth	factor	for	NK	cells		22	and	IL‐21,	which	is	involved	in	395 
regulation	of	NK,	B	and	T	cell	function	were	increased	at	24	hours	post	infection,	with	IL‐21	396 
expression	increased	more	than	5‐fold	23.	Most	studies	of	IL‐21	suggest	that	activated	CD4	397 
T	cells	are	the	primary	source	of	this	cytokine	24	so	increased	gene	expression	in	398 
endocervical	cells	was	unexpected.	Expression	of	these	two	cytokines	may	play	a	role	in	the	399 
early	recruitment	of	NK	cells	into	the	infected	genital	tract.	NK	cells	provide	an	important	400 
early	source	of	IFN ・,	which	is	essential	for	resolution	of	chlamydial	infections.	IL‐21	is	401 
also	important	for	the	development	of	Th17	cells	24,	which	are	increasingly	implicated	in	402 
the	control	of	genital	chlamydial	infections	25,26.		Intriguingly,	the	cytokine	that	showed	the	403 
greatest	up‐regulation	was	IL‐17C.	This	is	the	least‐well	studied	member	of	the	IL‐17	404 
family	of	cytokines	27.	T	cells	are	not	a	source	of	this	cytokine	and	mRNA	for	IL‐17C	has	405 
been	previously	reported	in	the	prostate,	kidney,	psoriatic	skin	and	infected	lung	tissues	in	406 
mice,	although	expression	may	be	more	restricted	in	humans	27,28.	IL‐17C	activates	NF‐kB	407 
and	stimulates	the	secretion	of	TNF	and	IL‐1	by	THP‐1	cells	and	contributes	to	the	408 
exacerbation	of	inflammatory	arthritis	in	mice	27,	29.	Interestingly,	we	also	found	IL‐17C	409 
mRNA	expression	in	Chlamydia‐infected	primary	endocervical	cells	(Figure	),	with	410 
expression	significantly	higher	in	cells	isolated	at	the	secretory	phase	of	the	reproductive	411 
cycle.	This	is	the	first	report	of	expression	of	IL‐17C	in	the	reproductive	tract.	412 
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Genes	for	two	recently	discovered	cytokines,	IL‐29	and	IL‐32,	were	up	regulated	in	413 
progesterone‐treated	infected	cells.	IL‐29	(IFN‐1)	is	a	member	of	the	type	III/ ‐interferon	414 
family	30.	These	cytokines	are	distantly	related	to	type	I	interferons,	and	activate	JAK‐STAT	415 
pathways	to	induce	antiviral	(including	HSV),	anti‐proliferative	and	antitumor	immune	416 
responses	(reviewed	in	31).	IL‐29/IFN‐1	may	inhibit	the	development	of	Th2	responses	by	417 
inhibiting	production	of	IL‐13,	IL‐4	and	IL‐5	32,	33,	which	could	promote	the	development	of	418 
protective	Th1	immunity	to	infection.	IL‐32	activates	p38MAPK	and	NF‐kB	pathways	and	is	419 
implicated	in	both	innate	and	adaptive	immune	responses	34.	IL‐32	increases	production	of	420 
TNF  IL‐1,	IL‐6 and	CXCL2/MIP‐2	in	a	dose‐dependent	manner	and	epithelial	cells	421 
from	colon,	lung	and	stomach	have	been	shown	to	secrete	IL‐32	34.	IL‐32	also	synergizes	422 
with	NOD‐1	and	NOD‐2	ligands	for	increased	production	of	the	pro‐inflammatory	cytokines	423 
IL‐1	and	IL‐6,	through	a	caspase‐1	dependent	mechanism	35.	At	least	3	species	of	424 
Chlamydia	(C.	trachomatis,	C.	muridarum	and	C.	pneumonia)	activate	host	inflammatory	425 
responses	in	part	through	NOD‐1	36‐39	suggesting	that	immune	activation	by	Chlamydia	426 
may	involve	IL‐32/NOD‐1	signalling	pathways.	Furthermore,	siRNA	knockdown	of	IL‐32	427 
reduces	the	secretion	of	Th1	cytokines	in	human	PBMC	40	suggesting	a	role	for	IL‐32	in	428 
driving	Th1	immunity.		429 
Type	1	interferon	pathways	were	also	activated	in	progesterone‐primed	and	infected	cells	430 
with	two	alpha	interferon	family	members	(IFNA1	and	IFNA14)	and	both	chains	of	the	431 
receptor	for	alpha	and	beta	interferons	(IFNAR1	and	IFNAR2)	significantly	increased.	Type	432 
1	interferons	inhibit	chlamydial	growth	in	human	epithelial	cells	in	a	L‐tryptophan‐433 
dependent	manner	41.	The	non‐ligand‐binding	chain	of	the	receptor	for	IFN	(IFNGR2)	was	434 
also	up‐regulated	at	24	hours	post‐infection.	A	receptor	for	IFN	would	be	required	on	435 
infected	epithelial	cells	for	induction	of	IDO‐mediated	tryptophan	depletion,	the	major	anti‐436 
chlamydial	response	in	human	cells	elicited	by	IFN	secreted	by	NK	and	CD4	T	cells	42.	437 
In	summary,	our	studies	have	shown	that	priming	of	endocervical	cells	with	progesterone,	438 
at	concentrations	found	during	the	luteal/secretory	phase	(20	ng/ml),	enhances	the	innate	439 
immune	response	elicited	by	C.	trachomatis	infection	resulting	in	a	5‐10‐fold	reduction	in	440 
IFU	compared	to	non‐hormone	or	estradiol‐treated	cells.	The	transcriptional	profile	in	441 
progesterone‐treated,	infected	cells	included	(i)	increased	expression	of	multiple	442 
antibacterial	mediators	(defensins,	chemokines,	S100	proteins),	(ii)	increased	pro‐443 
inflammatory	cytokines	(IL‐1,	IL‐6,	TNF ・)	(iii)	coordinated	expression	of	mediators	444 
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involved	in	immune	cell	recruitment	(chemokines,	adhesion	molecules,	integrins,	MMPs),	445 
(iv)	activation	of	both	type	I	and	type	II	interferon	pathways	and	(v)	production	of	446 
cytokines	that	enhance	Th1	immunity	(IL‐32)	and	suppress	Th2	cells	(IL‐29).	This	447 
contrasts	with	the	immunosuppressive	effects	of	progesterone	at	higher	concentrations	448 
found	during	pregnancy	(50‐200	ng/ml	in	the	third	trimester)	or	produced	locally	in	the	449 
placenta,	where	levels	can	reach	3000	ng/g	of	tissue	43,	which	are	required	to	maintain	450 
maternal	tolerance	to	the	fetus	44.	At	higher	doses	progesterone	suppresses	NK	cell	activity	451 
45,	promotes	the	development	of	Treg	cells	46	47,	promotes	Th2	development	over	Th1	48 48,	452 
suppresses	dendritic	cell	function	49	50	51	and	suppresses	antibody	production	5.	453 
Collectively	these	data	suggest	that	multiple	protective	anti‐chlamydial	immune	454 
mechanisms	are	primed	by	progesterone,	at	concentrations	found	during	the	secretory	455 
phase,	and	that	this	can	explain	the	reduced	susceptibility	to	infection	during	the	secretory	456 
phase.		457 
	458 
	459 
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Figure	legends	628 
Figure	1.	Following	pre‐treatment	with	sex	hormones,	C.	trachomatis	16SrRNA	levels	in	629 
ECC‐1	cells	were	determined	by	qRT‐PCR	at	24	hours	post	infection.	The	significance	of	630 
differences	in	chlamydial	genome	numbers	was	determined	by	one‐way	ANOVA.	Data	is	631 
presented	as	mean	+	SEM	of	triplicate	cultures	from	one	of	3	separate	experiments.	632 
 633 
Figure	2.	Global	transcriptome	analysis	of	ECC‐1	cells	following	treatment	with	sex	634 
hormones	and/or	C.	trachomatis	infection	635 
	636 
Figure	3.	Comparison	of	the	fold	change	of	normalised	data	obtained	from	qRT‐PCR	and	637 
microarray	for	the	transcripts	encoding	CCL20,	CX3CL1,	CXCL8/IL‐8,	IFNAR1	and	CXCL11	638 
at	24	hrs	post‐infection	of	ECC‐1	cells.	Data	are	from	one	of	3	separate	experiments.	639 
	640 
Figure	4.	The	fold‐change	in	cytokine	and	chemokine	gene	expression	between	C.	641 
trachomatis‐infected	versus	non‐infected	proliferative	(P,	n	=	10))	and	secretory	(S,	n	=	10)	642 
phase	primary	endocervical	cells	was	determined	by	qRT‐PCR.	The	dotted	line	represents	643 
the	mean	of	the	population.	Data	are	presented	as	the	mean	+	SEM.	The	asterisk	(*)	644 
indicates	genes	that	were	statistically	different.	645 
	646 
	647 
	648 
	 	649 
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Table	1.	Gene	targets	and	primer	sequences	used	to	quantify:	A.	Microarray	data,	and	B.	672 
Explanted	and	infected	endocervical	tissue	673 
A.	 Gene	 Accession	
No.	
Sense Antisense	
	 CCL20	 D86955	 5’‐TAACAGCACTCCCAAAGAAC‐3’	 5’‐GTAGCAGCACTGACATCAAA‐3’
	 CX3CL1	 U84487	 5’‐CTTGACCATTCTCCACCTTC‐3’	 5’‐CTCTAACCAGCCAGCAGCAG‐3’	
	 CXCL8/
IL‐8	 Y00787	 5’‐CAAACTTTCAGAGACAGCAG‐3’	 5’‐ACACAGTGAGATGGTTCCTT‐3’
	 IFNAR1	 P17181	 5’‐GTGCAGAGGGGCGGTGTGAC‐3’	 5’‐ACACAGTGAGATGGTTCCTT‐3’
	 CXCL11	 U66096	 5’‐	AGTCTTCCTGAATGAATGAC‐3’ 5’‐CTTTGTAAACTCCGATGGTA‐3’
	 C.trD	
16S	
rRNA	
D85721	 5’‐GCTTGTTGGTGGGGTAA‐3’	 5’‐CAGTGTTGGCGGTCAAT‐3’	
	674 
B.	 Gene	 Accession	No. Taqman	Gene	Expression	Assay	
number	
	 CX3CL1	 NM_002996.3 Hs00171086_m1	
	 CXCL8/IL‐8	 NM_000584.2 Hs00174103_m1	
	 CCL2	 NM_002982.3 Hs00234140_m1	
	 CCL20	 NM_004591.1 Hs00355476_m1	
	 IL‐6	 NM_000600.1 Hs00174131_m1	
	 CXCL10	 NM_001565.2 Hs00171042_m1	
	 IL‐17C	 NM_013278.3 Hs00171163_m1	
	 CXCL11	 NM_005409.3 Hs00171138_m1	
	 IL‐20	 NM_018724.3 Hs00218888_m1	
	 Selectin	E	 NM_000450.1 Hs00174057_m1	
	675 
	 	676 
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	677 
Table	2.	Host‐specific	immune	genes	compiled	from	the	microarray	data	that	were	678 
significantly	up‐regulated,	in	response	to	progesterone‐only	treatment,	sampled	at	12	hrs	679 
and	24	hrs	time‐points,	with	or	without	a	concurrent	C.trachomatis	D	infection.		680 
	681  	682 
Name p‐value fold‐ Name p‐va lue fold‐ Name p‐va lue fold‐ Name p‐value fold‐
PPBP 0.022 3.33 CCL20 0.000 8.00
CX3CL1 0.000 7.65
CXCL2 0.001 6.25
CXCL10 0.000 5.22
CCL5 0.000 3.81
CXCL9 0.039 1.70
CXCL13 0.015 2.60 CCL4 0.030 2.80 CXCL11 0.001 6.32
CXCL12 0.025 2.61 CCL2 0.001 5.56
CCL22 0.001 5.18
CCL17 0.008 3.83
CCL4L2 0.008 2.99
CXCL1 0.034 2.30
CXCL6 0.015 2.00
IL1B 0.001 4.83
IL6 0.000 4.10
IL7 0.007 2.02
IL24 0.030 3.17 IL29 0.042 2.11 IL17C 0.000 8.10
IL2 0.034 1.76 IL20 0.000 6.23
IL19 0.035 1.52 IL8 0.000 5.75
IL21 0.025 5.28
IL23A 0.000 2.95
IL32 0.001 2.57
IL15 0.005 2.00
MMP12 0.028 1.56 IL6ST 0.033 11.20
JAK1 0.038 6.24
S100A3 0.007 4.20
SOCS1 0.002 4.07
ICAM1 0.000 3.94
IFNGR2 0.000 3.49
MMP9 0.043 3.12
ITGAM 0.007 2.50
TLR5 0.039 2.34
IFNAR1 0.001 2.30
STAT6 0.017 2.27
ITFG1 0.023 6.01 IL20RB 0.036 2.94 DEFB129 0.001 6.08 S100A9 0.000 10.22
DEFB108B 0.005 2.66 IFNA1 0.024 4.41 DEFB4B 0.000 7.42
SOCS4 0.030 1.52 IFNA1 0.024 4.41 S100A8 0.000 4.90
DEFA4 0.044 3.98 IL1F9 0.001 4.25
TLR8 0.035 3.75 STAT5A 0.002 3.80
MMP25 0.007 3.70 MMP25 0.007 3.53
DEFB104A 0.007 3.17 ITGB8 0.002 3.22
IL8RB 0.029 2.95 IL1RAPL1 0.023 2.85
S100A5 0.021 2.66 S100A7 0.000 2.55
MMP3 0.038 2.53 IL18R1 0.003 2.44
MMP7 0.036 2.50 IFNAR2 0.009 2.05
S100A2 0.018 2.33 ITFG2 0.023 1.68
DEFB137 0.030 2.32 SOCS4 0.049 1.63
IL1F8 0.004 1.90
IL6R 0.049 1.84
IFNA14 0.048 1.69
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em
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